0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T18:55:00Z
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Fri 11 Oct 24, 01:15 PMInspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
Thu 10 Oct 24, 01:45 PMCRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Thu 10 Oct 24, 01:10 PMRBC Capital Markets upgrades Medtronic to 'outperform' on growth confidence
Thu 10 Oct 24, 09:38 AMMDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
Wed 09 Oct 24, 04:30 PMThe Zacks Analyst Blog JPMorgan, Medtronic, Shopify and Perma-Pipe International
Wed 09 Oct 24, 07:15 AMTop Research Reports for JPMorgan Chase, Medtronic & Shopify
Tue 08 Oct 24, 08:23 PMReturns On Capital At Medtronic (NYSE:MDT) Have Stalled
Tue 08 Oct 24, 11:00 AMMedtronic (MDT) Advances But Underperforms Market: Key Facts
Fri 04 Oct 24, 09:50 PM| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Income before tax | 5364.00M | 5517.00M | 3895.00M | 4055.00M | 5197.00M |
| Minority interest | -26.00000M | -22.00000M | 174.00M | 17.00M | 121.00M |
| Net income | 3758.00M | 5039.00M | 3606.00M | 4789.00M | 4631.00M |
| Selling general administrative | 10415.00M | 10292.00M | 10148.00M | 9875.00M | 10232.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 20508.00M | 21541.00M | 19634.00M | 19489.00M | 21402.00M |
| Reconciled depreciation | 2697.00M | 2707.00M | 2702.00M | 2663.00M | 2659.00M |
| Ebit | 5485.00M | 5752.00M | 4484.00M | 4791.00M | 7005.00M |
| Ebitda | 9042.00M | 8932.00M | 7933.00M | 8241.00M | 9664.00M |
| Depreciation and amortization | 3557.00M | 3180.00M | 3449.00M | 3450.00M | 2659.00M |
| Non operating income net other | 515.00M | 318.00M | 336.00M | 356.00M | 373.00M |
| Operating income | 5485.00M | 5752.00M | 4484.00M | 4791.00M | 6268.00M |
| Other operating expenses | 25397.00M | 25778.00M | 25222.00M | 23691.00M | 23925.00M |
| Interest expense | 636.00M | 553.00M | 925.00M | 1092.00M | 1444.00M |
| Tax provision | 1580.00M | 456.00M | 265.00M | -751.00000M | 547.00M |
| Interest income | 164.00M | 541.00M | 617.00M | 379.00M | 676.00M |
| Net interest income | -636.00000M | -553.00000M | -925.00000M | -1092.00000M | -1444.00000M |
| Extraordinary items | - | - | 106.00M | 63.00M | -12.00000M |
| Non recurring | -30.00000M | 95.00M | 118.00M | 313.00M | 166.00M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 1580.00M | 456.00M | 265.00M | -751.00000M | 547.00M |
| Total revenue | 31227.00M | 31686.00M | 30117.00M | 28913.00M | 30557.00M |
| Total operating expenses | 14678.00M | 15633.00M | 14739.00M | 14267.00M | 14770.00M |
| Cost of revenue | 10719.00M | 10145.00M | 10483.00M | 9424.00M | 9155.00M |
| Total other income expense net | -121.00000M | -235.00000M | -589.00000M | -736.00000M | 9.00M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 3784.00M | 5062.00M | 3630.00M | 4806.00M | 4650.00M |
| Net income applicable to common shares | 3758.00M | 5039.00M | 3606.00M | 4789.00M | 4631.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Total assets | 90948.00M | 90981.00M | 93083.00M | 90689.00M | 89694.00M |
| Intangible assets | 14844.00M | 15595.00M | 17740.00M | 19063.00M | 20560.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2425.00M | 2319.00M | 1956.00M | 2209.00M | 2144.00M |
| Total liab | 39283.00M | 38259.00M | 41481.00M | 39817.00M | 39482.00M |
| Total stockholder equity | 51483.00M | 52551.00M | 51428.00M | 50737.00M | 50091.00M |
| Deferred long term liab | 708.00M | 884.00M | 1028.00M | 1174.00M | 1278.00M |
| Other current liab | 6369.00M | 6376.00M | 6392.00M | 5594.00M | 5681.00M |
| Common stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M |
| Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | 30392.00M | 30250.00M | 28594.00M | 28132.00M | 26270.00M |
| Other liab | 6771.00M | 5493.00M | 5765.00M | 6656.00M | 6524.00M |
| Good will | 41425.00M | 40502.00M | 41961.00M | 39841.00M | 39959.00M |
| Other assets | -1.00000M | 1.00M | 1.00M | 3486.00M | 2108.00M |
| Cash | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
| Cash and equivalents | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
| Total current liabilities | 9051.00M | 12394.00M | 8509.00M | 10366.00M | 8472.00M |
| Current deferred revenue | - | - | - | - | 315.00M |
| Net debt | 22821.00M | 20400.00M | 22796.00M | 20657.00M | 20931.00M |
| Short term debt | 20.00M | 3742.00M | 11.00M | 2776.00M | 838.00M |
| Short long term debt | 20.00M | 3742.00M | 11.00M | 2771.00M | 832.00M |
| Short long term debt total | 24364.00M | 24114.00M | 26389.00M | 24797.00M | 25324.00M |
| Other stockholder equity | 24590.00M | 24566.00M | 26319.00M | 26165.00M | 26532.00M |
| Property plant equipment | 6610.00M | 5413.00M | 6219.00M | 4828.00M | 4675.00M |
| Total current assets | 21675.00M | 23059.00M | 22548.00M | 22031.00M | 21967.00M |
| Long term investments | - | - | - | - | 416.00M |
| Net tangible assets | 51483.00M | -3546.00000M | -8273.00000M | 50737.00M | -10428.00000M |
| Short term investments | 6416.00M | 6859.00M | 7224.00M | 6808.00M | 5455.00M |
| Net receivables | 5998.00M | 5551.00M | 5462.00M | 4645.00M | 6222.00M |
| Long term debt | 24344.00M | 20372.00M | 26378.00M | 21976.00M | 24476.00M |
| Inventory | 5293.00M | 4616.00M | 4313.00M | 4229.00M | 3753.00M |
| Accounts payable | 2662.00M | 2276.00M | 2106.00M | 1996.00M | 1953.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | 182.00M | 171.00M | 174.00M | 135.00M | 121.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | -3499.00000M | -2265.00000M | -3485.00000M | -3560.00000M | -2711.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | 30392.00M | 30250.00M | 28594.00M | 28132.00M | 26270.00M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7436.00M | 6411.00M | 5612.00M | 4926.00M | 2533.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 69274.00M | 67921.00M | 70534.00M | 68658.00M | 67727.00M |
| Capital lease obligations | 64.00M | 62.00M | 71.00M | 50.00M | 16.00M |
| Long term debt total | 24344.00M | 20372.00M | 26378.00M | 22021.00M | 24486.00M |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Investments | -3493.00000M | -190.00000M | -463.00000M | -1465.00000M | 2532.00M |
| Change to liabilities | 696.00M | 213.00M | 531.00M | -44.00000M | 399.00M |
| Total cashflows from investing activities | -3493.00000M | -1659.00000M | -2866.00000M | -3203.00000M | -774.00000M |
| Net borrowings | -598.00000M | -1.00000M | -570.00000M | -559.00000M | -713.00000M |
| Total cash from financing activities | -4960.00000M | -5336.00000M | -4136.00000M | -4198.00000M | -5431.00000M |
| Change to operating activities | - | -65.00000M | -549.00000M | -609.00000M | -624.00000M |
| Net income | 3784.00M | 5062.00M | 3630.00M | 4806.00M | 4650.00M |
| Change in cash | -2171.00000M | 121.00M | -547.00000M | -253.00000M | 724.00M |
| Begin period cash flow | 3714.00M | 3593.00M | 4140.00M | 4393.00M | 3669.00M |
| End period cash flow | 1543.00M | 3714.00M | 3593.00M | 4140.00M | 4393.00M |
| Total cash from operating activities | 6039.00M | 7346.00M | 6240.00M | 7234.00M | 7007.00M |
| Issuance of capital stock | 308.00M | 429.00M | 474.00M | 662.00M | 992.00M |
| Depreciation | 2697.00M | 2707.00M | 2702.00M | 2663.00M | 2659.00M |
| Other cashflows from investing activities | -1863.00000M | -10.00000M | -54.00000M | -525.00000M | 1827.00M |
| Dividends paid | -3616.00000M | -3383.00000M | -3121.00000M | -2894.00000M | 2693.00M |
| Change to inventory | -939.00000M | -560.00000M | 78.00M | -577.00000M | -274.00000M |
| Change to account receivables | -576.00000M | -477.00000M | -761.00000M | 1291.00M | -581.00000M |
| Sale purchase of stock | -645.00000M | -2544.00000M | -652.00000M | -1326.00000M | -2877.00000M |
| Other cashflows from financing activities | 7284.00M | 163.00M | 9694.00M | 5470.00M | 7095.00M |
| Change to netincome | 525.00M | 489.00M | 633.00M | -296.00000M | 778.00M |
| Capital expenditures | 1459.00M | 1368.00M | 1355.00M | 1213.00M | 1134.00M |
| Change receivables | -576.00000M | -477.00000M | -761.00000M | 1291.00M | -581.00000M |
| Cash flows other operating | -148.00000M | -65.00000M | -549.00000M | -609.00000M | -624.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -2414.00000M | 351.00M | -762.00000M | -167.00000M | 802.00M |
| Change in working capital | -967.00000M | -889.00000M | -701.00000M | 61.00M | -1080.00000M |
| Stock based compensation | 355.00M | 359.00M | 344.00M | 297.00M | 290.00M |
| Other non cash items | 396.00M | 711.00M | 687.00M | 722.00M | 792.00M |
| Free cash flow | 4580.00M | 5978.00M | 4885.00M | 6021.00M | 5873.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDT Medtronic PLC |
0.41 0.51% | 80.44 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| ABT Abbott Laboratories |
1.29 1.15% | 113.22 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.41 0.11% | 358.76 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| BSX Boston Scientific Corp |
1.08 1.23% | 89.11 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
| SEMHF Siemens Healthineers AG |
- -% | 55.83 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
20 On Hatch, Dublin, Ireland, 2
| Name | Title | Year Born |
|---|---|---|
| Mr. Geoffrey Straub Martha | Chairman & CEO | 1970 |
| Ms. Karen L. Parkhill | EVP, CFO, IT & Enterprise Excellence | 1965 |
| Mr. Ivan K. Fong | Exec. VP, Gen. Counsel & Sec. | 1961 |
| Mr. Robert J. W. ten Hoedt | Exec. VP & Pres of Global Regions | 1960 |
| Mr. Robert John White | Exec. VP & Pres of Medical Surgical Portfolio | 1963 |
| Mr. Mark Ploof | Sr. VP of Global Operations and Bus. Services | NA |
| Ms. Jennifer M. Kirk | Principal Accounting Officer, Global Controller & Chief Accounting Officer | 1975 |
| Dr. Laura Mauri M.D., M.Sc. | Sr. VP and Chief Scientific, Medical & Regulatory Officer | NA |
| Mr. Sean Lennon | Chief Information Officer | NA |
| Mr. Ryan Weispfenning | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...